Director Marc Stapley of Glaukos Corporation (NYSE:GKOS) sold 15,000 shares for $1.9 million on Jan. 22, 2026, following the exercise of stock options. Stapley’s direct ownership post-transaction is valued at approximately $4.71 million, representing 0.07% of outstanding shares with no options remaining. The transaction exceeded prior dispositions.

Glaukos Corporation, specializing in ophthalmic medical devices and pharmaceutical therapies, recently received FDA approval for its glaucoma treatment supplement. The company serves ophthalmologists and healthcare institutions globally, focusing on patients with glaucoma and related conditions. Despite a rough 2025, the stock is up 4.3% in January 2026, with potential short-term gains from the FDA approval.

Stapley’s transactions were pre-scheduled under a Rule 10b5-1 trading plan. Glaukos’ market capitalization is $6.85 billion, with revenue at $469.82 million and a net income of -$87.61 million. The company saw a 24.92% price decrease in 2025 but is up 4.3% in January 2026. The recent FDA approval may impact share prices positively.

The Motley Fool offers “Double Down” stock recommendations for potentially lucrative investments. Past recommendations for companies like Nvidia, Apple, and Netflix have shown significant returns. Current alerts for three companies are available through Stock Advisor, providing unique investment opportunities. Take advantage before it’s too late.

Adé Hennis has no position in the mentioned stocks, and The Motley Fool maintains a disclosure policy. “Director Sells GKOS 15,000 Shares for $1.9 Million” was originally published by The Motley Fool.

Read more at Yahoo Finance: Director Sells GKOS 15,000 Shares for $1.9 Million